The Hippo signaling pathway is a highly conserved kinase cascade that regulates organ size, cell proliferation, apoptosis, and tissue homeostasis. Originally discovered in Drosophila melanogaster as a regulator of tissue growth, this pathway has emerged as a critical player in neurodegenerative diseases, particularly Parkinson's Disease (PD). The pathway controls neuronal survival through a kinase cascade involving MST1/2, LATS1/2, and the downstream effectors YAP (Yes-Associated Protein 1) and TAZ (WWTR1).
In the context of Parkinson's Disease, the Hippo pathway has garnered significant attention due to its role in regulating dopaminergic neuron survival, its interaction with alpha-synuclein aggregation, and its cross-talk with mitochondrial quality control mechanisms. This page provides a comprehensive mechanism model linking Hippo pathway dysregulation to PD pathophysiology.
The Hippo pathway consists of a serial kinase cascade that ultimately controls the subcellular localization and activity of YAP and TAZ:
| Component | Gene | Cellular Function | PD Relevance |
|---|---|---|---|
| MST1 | MST1 Gene | Core kinase, stress sensor | Hyperactivated in PD, pro-apoptotic |
| MST2 | MST2 Gene | Redundant kinase function | Compensatory role in neuron survival |
| SAV1 | SAV1 | Scaffold protein | Forms complex with MST1/2 |
| LATS1 | LATS1 — Large Tumor Suppressor Kinase 1 | Kinase, phosphorylates YAP/TAZ | Tumor suppressor function |
| LATS2 | LATS2 | Redundant kinase | Ubiquitin-mediated degradation |
| MOB1A/B | MOB1A Gene | Scaffold for LATS activation | Essential for kinase cascade |
| YAP1 | YAP1 — Yes-Associated Protein 1 | Transcriptional co-activator | Pro-survival when nuclear |
| TAZ | WWTR1 (TAZ) — WW Domain Containing Transcription Regulator 1 | Transcriptional co-activator | Reduced in PD brains |
| TEAD1-4 | TEAD1 — TEA Domain Transcription Factor 1 | Partner transcription factors | YAP/TAZ nuclear partners |
Canonical (Hippo ON): Under homeostatic conditions, cellular stress activates MST1/2 kinases, which phosphorylate and activate LATS1/2 with SAV1 and MOB1A/B scaffolds. Activated LATS1/2 then phosphorylate YAP/TAZ at Ser127 (YAP) and Ser89 (TAZ). Phosphorylated YAP/TAZ bind 14-3-3 proteins and are retained in the cytoplasm, leading to proteasomal degradation. This prevents pro-survival gene transcription and maintains tissue homeostasis.
Non-canonical regulation: YAP/TAZ can be activated independently of the Hippo kinase cascade through:
Multiple studies have documented Hippo pathway dysregulation in PD patient brains:
MST1/2 activation: Post-mortem studies of substantia nigra from PD patients show increased MST1 phosphorylation (activation), correlating with disease severity.
YAP/TAZ nuclear exclusion: Immunohistochemistry reveals reduced nuclear YAP/TAZ in dopaminergic neurons of PD patients compared to age-matched controls.
TEAD target gene downregulation: Transcriptomic analysis of PD substantia nigra shows decreased expression of YAP/TEAD target genes involved in cell survival[1].
Toxin-based models:
Genetic models:
Alpha-synuclein (SNCA — Alpha-Synuclein) directly interacts with Hippo pathway components through multiple mechanisms:
YAP/TAZ binding: Alpha-synuclein can bind to YAP and TAZ proteins, affecting their subcellular localization and transcriptional activity[3].
TEAD competition: Alpha-synuclein can interfere with YAP/TAZ-TEAD binding, reducing pro-survival gene transcription.
Proteasomal interference: Aggregated alpha-synuclein impairs the proteasome, affecting YAP/TAZ degradation kinetics.
Through mitochondrial dysfunction:
Through autophagy inhibition:
The Hippo pathway intersects extensively with mitochondrial quality control mechanisms central to PD:
PINK1-Parkin pathway: PINK1 (PINK1 (PTEN-Induced Kinase 1) deficiency dysregulates MST1, leading to enhanced apoptosis. Parkin ([Parkin (PARK2) /genes/parkin]) can ubiquitinate YAP, affecting its stability.
Mitophagy regulation: YAP/TAZ regulate expression of autophagy genes. Reduced nuclear YAP/TAZ in PD impairs mitophagy initiation.
Mitochondrial dynamics: TEAD target genes include mitochondrial fusion proteins. Loss of YAP/TAZ signaling disrupts mitochondrial dynamics.
MST1 functions as an oxidative stress sensor:
ROS-activated kinase: MST1 is directly activated by reactive oxygen species through oxidation of cysteine residues.
Nrf2 cross-talk: YAP/TAZ can regulate Nrf2 (NFE2L2) target genes, linking Hippo signaling to antioxidant response.
Glutathione metabolism: TEAD target genes include GCLC and GCLM, key enzymes in glutathione synthesis.
Hippo pathway regulates microglial function and neuroinflammation:
Microglial YAP: YAP in microglia (Microglia — Neuroinflammation) controls inflammatory cytokine expression.
NF-κB cross-talk: YAP can interact with NF-κB, modulating neuroinflammatory response.
TNF-α signaling: Pro-inflammatory cytokines can activate MST1 in neurons.
| Target | Approach | Development Status | Examples |
|---|---|---|---|
| MST1/2 | Inhibitors | Preclinical | Verteporfin, Darapimod |
| YAP/TAZ | Activators | Preclinical | MST1 inhibitors to prevent degradation |
| TEAD | Agonists | Early research | Peptide agonists |
| LATS1/2 | Activators | Early research | Upstream kinase activators |
MST1 inhibitors: Small molecule inhibitors of MST1 kinase activity are being developed to block pro-apoptotic signaling in dopaminergic neurons.
YAP stabilization: Compounds that prevent YAP phosphorylation or promote nuclear localization are under investigation.
TEAD agonists: Synthetic peptides that activate TEAD-dependent transcription in neurons.
Currently, no clinical trials specifically target Hippo pathway in PD. However, several clinical trials for related compounds may have implications:
The Hippo signaling pathway represents a critical nexus linking multiple pathological mechanisms in Parkinson's Disease. From alpha-synuclein aggregation to mitochondrial dysfunction, Hippo pathway dysregulation contributes to dopaminergic neuron vulnerability through reduced YAP/TAZ pro-survival signaling and enhanced MST1-mediated apoptosis.
Key research directions include: